knowledge -WSS

knowledge

author：fashion 2025-10-02 18:49:59 - browse：9

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： How to ethically and practically extend health care to all

WSS

Sanders wants to replace patents with prizes for drug inventions

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Chris Christie meets with Zelenskyy during Ukraine trip

'CMA Fest' 2023: How to watch, who is performing and more

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Telehealth startups are trying to fill the menopause care vacuum

entertainment

knowledge

hotspot

Activists slam private health insurers over coverage restrictions

Alnylam reports growth in sales of rare disease treatments

How to save PrEP access — and even expand it

There’s a way to spot data fakery. All journals should be using it

State Dept. review finds Biden bears some blame for Afghanistan failures

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

How to save PrEP access — and even expand it

There’s a way to spot data fakery. All journals should be using it

Trump demands the U.S. pay no more for drugs than other countries … again

When a patient nears the end, a feared therapy can comfort

focus

Hormonal contraceptives don’t actually treat endometriosis

'Null' research findings aren't empty of meaning. Let's publish them

Sanders wants to replace patents with prizes for drug inventions

The cancer stories no one wants to hear

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Personalized medicine goes far beyond genetics

entertainment

hotspot

focus

leisure time